دورية أكاديمية
PRAME Immunohistochemistry for Distinguishing Vulvar and Vaginal Melanoma From Benign Melanocytic Nevi.
| العنوان: | PRAME Immunohistochemistry for Distinguishing Vulvar and Vaginal Melanoma From Benign Melanocytic Nevi. |
|---|---|
| المؤلفون: | Martin SD, Martin KC, Gilks CB, Crawford RI, Hoang LN |
| المصدر: | International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists [Int J Gynecol Pathol] 2024 Jul 01; Vol. 43 (4), pp. 389-396. Date of Electronic Publication: 2023 Dec 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8214845 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7151 (Electronic) Linking ISSN: 02771691 NLM ISO Abbreviation: Int J Gynecol Pathol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: New York : Raven Press, c1982- |
| مواضيع طبية MeSH: | Melanoma*/diagnosis , Melanoma*/pathology , Melanoma*/metabolism , Immunohistochemistry* , Nevus, Pigmented*/diagnosis , Nevus, Pigmented*/pathology , Nevus, Pigmented*/metabolism , Vulvar Neoplasms*/pathology , Vulvar Neoplasms*/diagnosis , Vulvar Neoplasms*/metabolism , Antigens, Neoplasm*/metabolism , Antigens, Neoplasm*/analysis , Biomarkers, Tumor*/analysis , Biomarkers, Tumor*/metabolism , Vaginal Neoplasms*/pathology , Vaginal Neoplasms*/diagnosis , Vaginal Neoplasms*/metabolism, Humans ; Female ; Middle Aged ; Diagnosis, Differential ; Aged ; Adult ; Aged, 80 and over ; Skin Neoplasms/pathology ; Skin Neoplasms/diagnosis ; Skin Neoplasms/metabolism ; Vulva/pathology ; Cohort Studies |
| مستخلص: | Vulvovaginal melanoma (VVM) is a rare but deadly disease, accounting for 5% of all vulvar malignancies, with a 5-yr survival rate of only 47% for all stages of the disease. VVM is a distinct subset of melanoma, with a unique genomic profile and underlying pathogenesis unassociated with sun exposure. Distinguishing these rare malignancies from very common pigmented lesions of the vulva and vagina is challenging as histologic features often overlap between entities. PReferentially expressed Antigen in MElanoma (PRAME) is a melanoma-associated protein, and immunohistochemistry (IHC) for PRAME distinguishes cutaneous, oral mucosal, and retinal melanoma from atypical nevi. Given the biological differences between VVM and cutaneous melanoma, the utility of PRAME IHC for the diagnosis of VVM is unknown. We accrued a cohort of 20 VVM and 21 benign vulvar melanocytic nevi. We found that nuclear PRAME IHC staining with 4+ intensity was present in 85% of the VVM and 0% of the nevi. With the assistance of PRAME IHC, we found evidence of close or positive margin involvement in 3 of 10 cases where margins were originally diagnosed as negative for melanoma in situ. Our study is the first to assess PRAME IHC in a cohort of VVM cases and provides confidence for using PRAME IHC to assist with diagnosis and margin assessment in this rare disease. Competing Interests: The authors declare no conflict of interest. (Copyright © 2023 by the International Society of Gynecological Pathologists.) |
| References: | Wohlmuth C, Wohlmuth-Wieser I. Vulvar melanoma: molecular characteristics, diagnosis, surgical management, and medical treatment. Am J Clin Dermatol 2021;22:639–51. Wohlmuth C, Wohlmuth-Wieser I, May T, et al. Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients. Am J Clin Dermatol 2020;21:285–95. Michielin O, van Akkooi ACJ, Ascierto PA, et al. clinicalguidelines@esmo.org EGCEa. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2019;30:1884–901. Ortmann CA, Eisele L, Nuckel H, et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 2008;87:809–18. Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME expression in melanocytic tumors. Am J Surg Pathol 2018;42:1456–65. Brenne K, Nymoen DA, Reich R, et al. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Pathol 2012;137:240–7. Steger B, Floro L, Amberger DC, et al. WT1, PRAME, and PR3 mRNA expression in acute myeloid leukemia (AML). J Immunother 2020;43:204–15. Neumann E, Engelsberg A, Decker J, et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 1998;58:4090–5. Epping MT, Hart AA, Glas AM, et al. PRAME expression and clinical outcome of breast cancer. Br J Cancer 2008;99:398–403. Kaczorowski M, Chlopek M, Kruczak A, et al. PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol 2022;46:1467–76. Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835–47. Lezcano C, Jungbluth AA, Busam KJ. PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin 2021;14:165–75. Schmitt TA, Lee JC, Martinka M, et al. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules. J Cutan Pathol 2023;50:275–8. Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res 2016;22:1234–42. Toyama A, Siegel L, Nelson AC, et al. Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas. Mod Pathol 2019;32:1727–33. Hou JY, Baptiste C, Hombalegowda RB, et al. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer 2017;123:1333–44. Tseng D, Kim J, Warrick A, et al. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol 2014;71:229–36. Banyi N, Alex D, Hughesman C, et al. Improving time-to-treatment for advanced non-small cell lung cancer patients through faster single gene EGFR testing using the Idylla EGFR testing platform. Curr Oncol 2022;29:7900–11. Gradecki SE, Valdes-Rodriguez R, Wick MR, et al. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology 2021;78:1000–8. Kunc M, Zemierowska N, Skowronek F, et al. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions. Histopathology 2023;83:3–14. Lorenz A, Kozlowski M, Lenkiewicz S, et al. Cutaneous melanoma versus vulvovaginal melanoma-risk factors, pathogenesis and comparison of immunotherapy efficacy. Cancers (Basel) 2022;14:5123. Aulmann S, Sinn HP, Penzel R, et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol 2014;27:1386–93. Shojiguchi N, Takai S, Arai E. Hyperplastic melanocytes with chromosomal aberrations in surrounding skin of subungual melanoma: fluorescence in situ hybridisation analysis using whole-slide digital imaging. Histopathology 2022;81:808–17. |
| المشرفين على المادة: | 0 (PRAME protein, human) 0 (Antigens, Neoplasm) 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20231212 Date Completed: 20240613 Latest Revision: 20240613 |
| رمز التحديث: | 20240613 |
| DOI: | 10.1097/PGP.0000000000001004 |
| PMID: | 38085951 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1538-7151 |
|---|---|
| DOI: | 10.1097/PGP.0000000000001004 |